Thus, the potent activity of PLT3 in lowering cholesterol and protecting from atherosclerosis and hepatic steatosis is likely to be mediated by elevated adipocytes beiging, increased adiponectin level, and reduced proinflammatory cytokines or altered secretion of other unknown adipokines. This evidence concerns the gene ADIPOQ and fatty liver disease.